Christopher Austin MD, Director of NCATS, will assemble a group of stakeholders to provide advice to begin rapid implementation of the recommendations. One of the first tasks will be development of clear, measurable goals for the program that address critical issues across the full spectrum of clinical and translational research. While engaging with stakeholders, NCATS also will increase its direct and active leadership of the CTSA program, including addressing the recommendation to streamline program governance. Dr. Austin will keynote the ICTR’s annual Symposium on November 8th, 2013 in the Price Center. His talk, Catalyzing Translational Innovation in Medicine for the 21st Century, will also address the IOM’s recommendations. The full report is at http://www.ncats.nih.gov/about/faq/iom-ctsa/iom.html

What are the implications for the Einstein-Montefiore ICTR? We just received the great news that our CTSA grant application was very favorably reviewed, and the ICTR’s strategic plan is very well aligned with the thrust of the IOM recommendations. Thus, we look forward to the next phase of refining “CTSA 2.0” as members of the CTSA Consortium, and to continue to serve our research community — you!

Sofiya Milman MD, MS, assistant professor of medicine (Endocrinology) was awarded a CDA for her project, “Effect of protective longevity genotypes on phenotype and CVD outcomes.” Dr. Milman completed the Einstein CRTP, from which she was awarded her MS degree. She will utilize 2 established cohorts with exceptional longevity to determine genetic factors associated with endothelial function and CVD. Dr. Milman’s mentor is Nir Barzilai MD; her co-mentors are Jill Crandall MD, and Gil Atzmon PhD.

LECTURE SERIES
Application deadline: August 31, 2013
For more information, call 430-2660